Cassava Sciences Inc. (NASDAQ:SAVA) has announced that its phase 2b clinical study results for sumifilam have been picked for late-breaking oral presentation by the Clinical Trials on Alzheimer’s Disease’s (CTAD) 13th international conference.
Cassava to present phase 2b sumifilam study results at CTAD
CTAD is an important annual conference that focuses on Alzheimer’s research and development. The conference will be held virtually this year between November 4, 2020, and November 7, 2020. Each year the scientific committee members of CTAD select some research abstract to be presented during the conference based on scientific and medical significance, methodology, and quality data. The late-breaking presentation of Cassava is titled, ”Sumifilam (PTI-125) Significantly Improves Eleven CSF Biomarkers in A Randomized, Placebo-Controlled, One-Month Clinical Trial in Alzheimer’s Disease Patients.” The company will make the CTAD presentation available on its website on the day of the presentation.
Recently the company announced the final results of the phase 2b sumifilam study, which is its lead Alzheimer’s disease drug candidate. The National Institutes of Health (NIH) funded the clinical study in which patients received 50mg or 100mg of sumifilam twice per day for four weeks.
Sumifilam showed benefits in Alzheimer’s disease patients
Results showed statistically significant improvements in disease pathology biomarkers, neuroinflammation, and neurodegeneration in study participants compared to those in the placebo group. Also, patients treated with sumifilam demonstrated significant improvement in certified episodic memory tests and spatial working memory against those in placebo. The cognitive benefits reported were strongly correlated with the drop in P-tau181 levels.
The results indicate promising treatment benefits for patients with mild-to-moderate Alzheimer’s disease that received sumifilam in the study. Treatment in the trial with sumifilam for four weeks resulted in an improvement in the entire panel of validated Alzheimer’s disease biomarkers. Also, decreased neuroinflammation measurements showed a responder rate of 98%, was well-tolerated and safe, and tended to benefit cognition. Most importantly, the results are consistent with previous preclinical and clinical data regarding the action mechanism and more than 10 years of research.